In this issue:
Darbepoetin alfa for MDS
Long-term remission with cladribine then rituximab in HCL
Pegfilgrastim vs. filgrastim for managing neutropenia during CHASE(R)
Long-term outcomes for ruxolitinib vs best available therapy for myelofibrosis
MSCs for preventing chronic GVHD after HLA-haploidentical SCT
CML life expectancy approaches that of general population
Nivolumab for relapsed/refractory haematological malignancies
Edoxaban for VTE in cancer patients
High-dose chemotherapy with SCT for primary CNS lymphoma
Please login below to download this issue (PDF)